Key points are not available for this paper at this time.
Abstract Despite its importance in human cancers, including colorectal cancers (CRC), oncogenic KRAS has been extremely challenging to target therapeutically. To identify potential vulnerabilities in KRAS-mutated CRC, we characterize the impact of oncogenic KRAS on the cell surface of intestinal epithelial cells. Here we show that oncogenic KRAS alters the expression of a myriad of cell-surface proteins implicated in diverse biological functions, and identify many potential surface-accessible therapeutic targets. Cell surface-based loss-of-function screens reveal that ATP7A, a copper-exporter upregulated by mutant KRAS, is essential for neoplastic growth. ATP7A is upregulated at the surface of KRAS-mutated CRC, and protects cells from excess copper-ion toxicity. We find that KRAS-mutated cells acquire copper via a non-canonical mechanism involving macropinocytosis, which appears to be required to support their growth. Together, these results indicate that copper bioavailability is a KRAS-selective vulnerability that could be exploited for the treatment of KRAS-mutated neoplasms.
Building similarity graph...
Analyzing shared references across papers
Loading...
Léo Aubert
Institute for Research in Immunology and Cancer
Neethi Nandagopal
Institute for Research in Immunology and Cancer
Zachary Steinhart
Gladstone Institutes
Nature Communications
University of Toronto
McGill University
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Aubert et al. (Fri,) studied this question.
synapsesocial.com/papers/6a0ff18d5725bbd5cc60486b — DOI: https://doi.org/10.1038/s41467-020-17549-y
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: